Airway inflammation and cough sensitivity in cough‐variant asthma

Diego, A. De; Martinez, Edson Zangiacomi; Perpiñá, M.; Nieto, Laurence; Compte, L.; Macián, V.; Senent, Leonor

doi:10.1111/j.1398-9995.2005.00609.x

Cited by 50 publications

(35 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Liu et al [32] demonstrated that antigen-induced increases in cough response resulted from the increased cough reflex sensitivity. Airway allergy accompanied with airway eosinophilia induced increases in cough response, which was also supported by other studies [33,34]. Liu et al [32] also found that the increased cough sensitivity may result in part from inactivation of neutral endopeptidase and thromboxaneA2 (TXA2), inflammatory mediators.…”

Section: Discussionmentioning

confidence: 73%

Therapeutic effects of naringin in a guinea pig model of ovalbumin-induced cough-variant asthma

Jiao¹,

et al. 2015

Pulmonary Pharmacology & Therapeutics

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 73%

Therapeutic effects of naringin in a guinea pig model of ovalbumin-induced cough-variant asthma

Jiao¹,

et al. 2015

Pulmonary Pharmacology & Therapeutics

View full text Add to dashboard Cite

“…De Diego et al [43] reported that although classic asthma and CVA have similar profiles of airway inflammatory markers their relationships with AHR and cough sensitivity differ. Lee et al [10] found increased SP-immunoreactive nerve densities in patients with CVA but not in those with classic asthma.…”

Section: Discussionmentioning

confidence: 99%

Plasma Substance P Levels in Patients with Persistent Cough

et al. 2011

View full text Add to dashboard Cite

Background: Substance P (SP) is involved in the pathogenesis of cough in animal models. However, few studies in humans have been reported and the roles of SP in clinical cough remain obscure. Objectives: To clarify the relevance of plasma levels of SP in patients with persistent cough. Methods: We studied 82 patients with cough persisting for at least 3 weeks and 15 healthy controls. Patients were classified as having asthmatic cough (cough-variant asthma and cough-predominant asthma; n = 61) or nonasthmatic cough (n = 21; postinfectious cough, n = 6; gastroesophageal reflux disease, n = 5; idiopathic cough, n = 5, and others, n = 5). Correlations were evaluated between plasma SP levels as measured with ELISA and methacholine airway hyperresponsiveness (airway sensitivity and airway reactivity), capsaicin cough sensitivity, sputum eosinophil and neutrophil counts, and pulmonary function. Results: Plasma SP levels were significantly elevated in patients with both asthmatic and nonasthmatic cough compared with controls [31.1 pg/ml (range 18.0–52.2) and 30.0 pg/ml (range 15.1–50.3) vs. 15.4 pg/ml (range 11.3–23.7); p = 0.003 and p = 0.038, respectively] but did not differ between the two patient groups (p = 0.90). Plasma SP levels correlated with airway sensitivity (threshold dose of methacholine) in the patients with asthmatic cough (r = –0.37, p = 0.005) but not with airway reactivity, cough sensitivity, FEV₁ values, or sputum eosinophil and neutrophil counts in either group. Conclusions: Increased levels of SP in plasma are associated with persistent cough in humans and might be related to airway sensitivity in asthmatic cough.

show abstract

“…The results of studies have shown that BAL and sputum in patients with CVA contain an increased percentage of eosinophils [2]. Also, the studies showed that there was no significant difference between CVA and classic asthma in the sputum levels of eosinophilic cationic protein, interleukin 8 (IL-8) and levels of exhaled nitric oxide (FeNO) [2,7,12,17,18]. Studies have suggested that the basic pathophysiological characteristics of CVA are eosinophilic inflammation and AHR [3].…”

Section: Pathological Mechanism Underlying Cvamentioning

confidence: 98%

Cough Variant Asthma as a Phenotype of Classic Asthma

Vujnović¹,

Domuz²,

Petrovic³

2018

Asthma Diagnosis and Management - Approach Based on Phenotype and Endotype

View full text Add to dashboard Cite

Cough variant asthma (CVA) was first described by Glauser. CVA was described as the isolated chronic cough as the only presenting symptom responsive to bronchodilator therapy. The authors now suggest that CVA is present with airway hyperresponsiveness, eosinophilic inflammation of central and peripheral airways and bronchodilator responsive coughing without typical manifestation of asthma such as wheezing or dyspnea. Pathologically, CVA shares common features such as eosinophilic inflammation and remodeling changes with classic asthma. Because of that, CVA is clinically considered as a variant type of asthma, a phase at the beginning of asthma pathogenesis or as a precursor of classic asthma. Nearly 30% of patients with CVA eventually develop intermittent wheezing, an average of 3-5 years. It is clinically very important to recognize CVA because long-term inhaled corticosteroids can significantly decrease the development of classic asthma in these patients.

show abstract

Airway inflammation and cough sensitivity in cough‐variant asthma

Abstract: Although the pattern of inflammatory sputum markers in patients with asthma and cough-variant asthma is similar, its relation with bronchial hyperreactivity and cough sensitivity is different in each group.

Cited by 50 publications

References 25 publications

Therapeutic effects of naringin in a guinea pig model of ovalbumin-induced cough-variant asthma

Therapeutic effects of naringin in a guinea pig model of ovalbumin-induced cough-variant asthma

Plasma Substance P Levels in Patients with Persistent Cough

Cough Variant Asthma as a Phenotype of Classic Asthma

Contact Info

Product

Resources

About